Clinical Report: Addressing the Accessibility Challenges of PSMA PET/CT

Background

Imaging plays a crucial role in the management of prostate cancer, particularly in staging and restaging, which directly impacts treatment choices. PSMA PET/CT has demonstrated superior diagnostic accuracy compared to conventional imaging methods, yet access remains inconsistent due to various systemic barriers.

Data Highlights

No numerical data available in the source material.

Key Findings

• PSMA PET/CT shows higher diagnostic accuracy (92%) compared to CT and bone scintigraphy (65%) for high-risk localized prostate cancer.
• In biochemical recurrence, PSMA PET/CT can identify disease at low PSA levels, with positivity rates of approximately 48% for PSA 0.2–0.5 ng/mL.
• Access to PSMA PET/CT is influenced by factors such as geography, hospital type, and reimbursement arrangements.
• Timely access to PSMA PET/CT is critical for its findings to effectively influence treatment decisions.
• Implementation barriers must be addressed to ensure equitable access to PSMA PET/CT across different patient populations.

Clinical Implications

Healthcare providers should be aware of the disparities in access to PSMA PET/CT and advocate for policies that promote equitable implementation. Understanding the diagnostic advantages of PSMA PET/CT can guide clinical decision-making in prostate cancer management.

Conclusion

Addressing the accessibility challenges of PSMA PET/CT is vital for optimizing prostate cancer treatment pathways. Ensuring timely access can significantly enhance patient care and outcomes.

Related Resources & Content

1. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study - PubMed, 2020
2. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY) - PubMed, 2021
3. Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase 3, Multicenter Study - PMC, 2021
4. True-Positive 18F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study - PMC, 2021
5. Comparison of Prostate-Specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities in the Detection of Biochemical Recurrence of Prostate Cancer - PubMed, 2023
6. ASCO Publications — Prostate-specific membrane antigen (PSMA) PET-CT guided radiotherapy in oligometastatic prostate cancer.
7. ASCO Publications — The IMPACT of 68GA-PSMA-PET in definitive radiotherapy planning for prostate cancer patients.
8. ASCO Publications — The CHAPPP study: Changing care with PSMA-PET for prostate cancer—A retrospective study of the role of PSMA imaging in altering treatment pathways.
9. ASCO Publications — Updated experience on PSMA PET/CT for recurrent prostate cancer in a high-volume Brazilian center.
10. 2025 EAU Guidelines on Prostate Cancer
11. NCCN Guidelines Version 1.2025 for Prostate Cancer
12. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study - PubMed
13. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY).
14. Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase 3, Multicenter Study - PMC
15. True-Positive 18F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study - PMC
16. Comparison of Prostate-Specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities in the Detection of Biochemical Recurrence of Prostate Cancer and Assessment of the Role of Artificial Intelligence: A Systematic Review and Meta-analysis - PubMed
17. The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A Systematic Review and Meta-analysis - ScienceDirect